CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit
CytoSorbents Corporation (NASDAQ: CTSO) has announced its participation in the UBS Global Healthcare Virtual Conference and the Oppenheimer MedTech, Tools, and Diagnostic Summit on May 26, 2021. The company will present an overview of its progress and outlook, along with conducting one-on-one meetings with investors. CytoSorbents specializes in blood purification technology, particularly its CytoSorb® product, which is approved in the EU and utilized in over 131,000 treatments globally.
- None.
- None.
MONMOUTH JUNCTION, N.J., May 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the UBS Global Healthcare Virtual Conference and provide a prerecorded presentation at the Oppenheimer MedTech, Tools and Diagnostic Summit on Wednesday, May 26, 2021. Company management will also meet with investors in 1x1 meetings throughout the day. To schedule a meeting with management, please contact your UBS and Oppenheimer representative.
UBS Healthcare Conference
When: Wednesday, May 26, 2021 from 3:00-3:30PM EDT
Webcast: UBS Healthcare Conference Webcast Link
A live webcast of the presentation will be available at the above webcast link. An archived replay of the webcast will be available for 30 days following the event.
Oppenheimer MedTech, Tools and Diagnostic Summit
When: Wednesday, May 26, 2021
Webcast: Oppenheimer Summit Webcast Link
A live webcast of the presentation will be available at the above webcast link. An archived replay of the webcast will be available for 90 days following the event.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in treating life-threatening conditions in critical care and cardiac surgery, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 68 countries outside of the US, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that may result in massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death may be extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 131,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma), and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than
FAQ
When will CytoSorbents present at the UBS Global Healthcare Conference?
What is the focus of CytoSorbents' presentations at the conferences?
What is CytoSorb® and its significance?
How many treatments have been performed using CytoSorb®?
Where can I find more information about CytoSorbents Corporation?
